Natural immunity and HIV disease progression
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Natural immunity and HIV disease progression. / Ullum, H; Cozzi-Lepri, A; Aladdin, H; Katzenstein, T; Victor, J; Phillips, A N; Gerstoft, J; Skinhøj, P; Klarlund Pedersen, B.
In: AIDS (London, England), Vol. 13, No. 5, 01.04.1999, p. 557-63.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Natural immunity and HIV disease progression
AU - Ullum, H
AU - Cozzi-Lepri, A
AU - Aladdin, H
AU - Katzenstein, T
AU - Victor, J
AU - Phillips, A N
AU - Gerstoft, J
AU - Skinhøj, P
AU - Klarlund Pedersen, B
PY - 1999/4/1
Y1 - 1999/4/1
N2 - OBJECTIVE: To investigate the clinical implications of impaired levels of the natural immunity mediated by natural killer (NK) cells and lymphokine activated killer (LAK) cells during infection with HIV-1.DESIGN: Data used were from 172 individuals with an estimated measure of NK cell activity and 146 with an estimated measure of LAK cell activity. Patients had active HIV infection at the time of enrolment in the study and have been followed-up prospectively for a median of 3.0 years.METHODS: The lytic activity of NK cells and LAK cells, the CD4 T lymphocyte count, and the concentration of CD16/CD56 NK cells were measured at enrolment. HIV RNA in plasma was measured retrospectively. Survival analysis was performed considering three main endpoints: CD4 cell counts below 100 x 10(6) cells/l, clinical AIDS, and death.RESULTS: In unadjusted analysis and after adjustment for age, CD4 T lymphocyte count and plasma HIV RNA at enrolment, low LAK cell activity was significantly associated with higher risk of progression to a CD4 T lymphocyte count < 100 x 10(6) cells/l (crude P = 0.001; adjusted P = 0.04) and to death (crude P = 0.0002; adjusted P = 0.02). Patients with low NK cell responsiveness to interferon-alpha tended to be at higher risk of death (crude P = 0.04; adjusted P = 0.13) whereas unstimulated NK cell activity and the concentration of NK cells were of no prognostic value for patients in this cohort.CONCLUSIONS: The present study suggests that low LAK cell activity and low NK cell responsiveness to interferon-alpha may be important in the pathogenesis of HIV infection.
AB - OBJECTIVE: To investigate the clinical implications of impaired levels of the natural immunity mediated by natural killer (NK) cells and lymphokine activated killer (LAK) cells during infection with HIV-1.DESIGN: Data used were from 172 individuals with an estimated measure of NK cell activity and 146 with an estimated measure of LAK cell activity. Patients had active HIV infection at the time of enrolment in the study and have been followed-up prospectively for a median of 3.0 years.METHODS: The lytic activity of NK cells and LAK cells, the CD4 T lymphocyte count, and the concentration of CD16/CD56 NK cells were measured at enrolment. HIV RNA in plasma was measured retrospectively. Survival analysis was performed considering three main endpoints: CD4 cell counts below 100 x 10(6) cells/l, clinical AIDS, and death.RESULTS: In unadjusted analysis and after adjustment for age, CD4 T lymphocyte count and plasma HIV RNA at enrolment, low LAK cell activity was significantly associated with higher risk of progression to a CD4 T lymphocyte count < 100 x 10(6) cells/l (crude P = 0.001; adjusted P = 0.04) and to death (crude P = 0.0002; adjusted P = 0.02). Patients with low NK cell responsiveness to interferon-alpha tended to be at higher risk of death (crude P = 0.04; adjusted P = 0.13) whereas unstimulated NK cell activity and the concentration of NK cells were of no prognostic value for patients in this cohort.CONCLUSIONS: The present study suggests that low LAK cell activity and low NK cell responsiveness to interferon-alpha may be important in the pathogenesis of HIV infection.
KW - CD4 Lymphocyte Count
KW - Disease Progression
KW - HIV Infections
KW - HIV-1
KW - Humans
KW - Immunity, Innate
KW - Killer Cells, Lymphokine-Activated
KW - Killer Cells, Natural
KW - Viral Load
KW - Journal Article
KW - Research Support, Non-U.S. Gov't
M3 - Journal article
C2 - 10203380
VL - 13
SP - 557
EP - 563
JO - AIDS
JF - AIDS
SN - 1350-2840
IS - 5
ER -
ID: 180572229